Rely on the most comprehensive, up-to-date legal content designed and curated by lawyers for lawyers
Work faster and smarter to improve your drafting productivity without increasing risk
Accelerate the creation and use of high quality and trusted legal documents and forms
Streamline how you manage your legal business with proven tools and processes
Manage risk and compliance in your organisation to reduce your risk profile
Stay up to date and informed with insights from our trusted experts, news and information sources
Access the best content in the industry, effortlessly — confident that your news is trustworthy and up to date.
With over 30 practice areas, we have all bases covered. Find out how we can help
Our trusted tax intelligence solutions, highly-regarded exam training and education materials help guide and tutor Tax professionals
Regulatory, business information and analytics solutions that help professionals make better decisions
A leading provider of software platforms for professional services firms
In-depth analysis, commentary and practical information to help you protect your business
LexisNexis Blogs shed light on topics affecting the legal profession and the issues you're facing
Legal professionals trust us to help navigate change. Find out how we help ensure they exceed expectations
Lex Chat is a LexisNexis current affairs podcast sharing insights on topics for the legal profession
Discuss the latest legal developments, ask questions, and share best practice with other LexisPSL subscribers
As part of our sector-focused series, we have curated the key resources and points you need to know from the last quarter’s legal updates. Understand the key news stories, practice notes, trackers and upcoming webinars specific to the Life Sciences industry.
1. Supreme Court—Unilever involved in dispute with inventor and fined £2m
Mark Daniels, partner and head of patents at Browne Jacobson LLP, examines the Supreme Court’s decision in Shanks v Unilever plc  UKSC 45,  All ER (D) 139 (Oct) that, under section 40 of the Patents Act 1977, the appellant inventor (Professor Shanks) was entitled to compensation of £2m from the group of companies of which his employer was part. The court held that £2m would give him a fair share of the outstanding benefit that the group had derived from the invention and various patents relating to it.
See News Analysis: Supreme Court—inventor entitled to fair share from employer of £2m (Shanks v Unilever Plc and others).
2. Human Medicines and Medical Devices Regulations 2019
The Human Medicines and Medical Devices (Amendment etc) (EU Exit) Regulations 2019, SI 2019/1385: this enactment is made in exercise of legislative powers under the European Union (Withdrawal) Act 2018 in preparation for Brexit. This enactment amends UK subordinate legislation in relation to the regulation of human medicines and medical devices in order to ensure that the published policy in the event that no deal is reached on the UK’s withdrawal from the EU is properly reflected in those legislation. It comes into force immediately before exit day. (Updated from draft on 28 October 2019.)
See: LNB News 25/07/2019 9.
3. European Commission sets out good practice to assess GMO for gene therapy products
The European Commission has updated its advanced therapies website to include a document on good practice on the assessment of genetically modified organisms (GMO)-related aspects in the context of clinical trials with Adeno-associated virus (AAV) clinical vectors as part of its GMO section dealing with GMO requirements for investigational products.
Access this article and thousands of others like it free by subscribing to our blog.
Read full article
Already a subscriber? Login
Amy leads the thought leadership and content strategy for LexisNexis UK. Her work appears in LexisNexis' marketing campaigns, industry press and legal industry magazines. She is an established writer and researcher, having contributed in national publications, such as City A.M. and Financial IT. She is also one of the writers and digital editors of LexisNexis' insights blogs, the Future of Law and the In-house blog.
0330 161 1234